Fundraising Fox

Artax Biopharma

Cambridge, US · Founded 2013 · 3 known investors

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.

BiotechHealthtech

Founders & leadership

Artax Biopharma was founded in 2013 by Damia Tormo.

DTDamia Tormo
Damia TormoPresident, CEO, Treasurer and Founder
JSJoe Suarez
Joe SuarezExecutive
MN
Maria NicholExecutive
RW
Robert W. Armstrong, Ph.D.Executive
RA
Rob ArmstrongCEO

Board

AH
Andre HoekemaBoard director
AWAlan Walts
Alan Waltsin𝕏Board directorVenture Partner at Advent Life Sciences
DT
Damia Tormo, Ph.D.Board director
CB
Casper BreumBoard director
RPRaj Parekh
Raj ParekhinBoard directorGeneral Partner at Advent Life Sciences
JG
Javier GarciaBoard director
GS
Gino SantiniBoard director

Investors · 3

Sound BioventuresMalmö
Advent Life SciencesreportedLondonvia Raj Parekh · board
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred

Reported raises · per SEC filings

Form D private placements

$54.7M disclosed across 7 rounds · 2014–2024

▶$19MraisedMay 2026 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joe SuarezExecutive Officer
  • Andre HoekemaDirector
  • Maria NicholExecutive Officer
  • Alan WaltsDirector
  • Damia Tormo, Ph.D.Director
  • Gino SantiniDirector
  • Casper BreumDirector
  • Raj ParekhDirector
  • Robert W. Armstrong, Ph.D.Executive Officer, Director
Offering amount
$19M
Amount sold
$19M
Proceeds to insiders
$3.5M
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.8MraisedMay 2022 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan E. WaltsDirector
  • Raj ParekhDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Casper BreumDirector
  • Robert Armstrong, Ph.D.Director
  • Gino SantiniDirector
  • Damia Tormo, Ph.D.Director
Offering amount
$25.8M
Amount sold
$25.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedFeb 2021 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gino SantiniDirector
  • Damia TormoDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Robert Armstrong, Ph.D.Director
  • Alan E. WaltsDirector
Offering amount
$3M
Amount sold
$2.2M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMay 2020 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan E. WaltsDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Javier GarciaDirector
  • Robert Armstrong, Ph.D.Director
  • Gino SantiniDirector
  • Damia Tormo, Ph.D.Director
Offering amount
$2M
Amount sold
$2M
First sale
Apr 2020
Incorporated
Corporation, Massachusetts
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750KraisedAug 2019 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Damia Tormo, Ph.D., MBMExecutive Officer, Director
  • Robert Armstrong, Ph.D.Director
  • Alan E. WaltsDirector
  • Gino SantiniDirector
  • Javier GarciaDirector
Offering amount
$3.5M
Amount sold
$750K
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedOct 2015 · 29 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Raj ParekhDirector
  • Gino SantiniDirector
  • Damia TormoExecutive Officer, Director
  • Henri TermeerDirector
  • Peter B. FinnExecutive Officer
  • Javier GarciaDirector
  • Robert W. Armstrong, Ph.D.Director
Offering amount
$10M
Amount sold
$3M
Minimum investment
$5K
Proceeds to insiders
$250K
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2014 · 18 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Jan de Vries, Ph.D.Director
  • Peter B. FinnExecutive Officer
  • Robert W. Armstrong, Ph.D.Director
  • Gino SantiniDirector
  • Damia TormoExecutive Officer, Director
  • Javier GarciaDirector
Offering amount
$2M
Amount sold
$2M
Minimum investment
$5K
Proceeds to insiders
$349.8K
First sale
Jul 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap
Adarx14 shared keywordsADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
Exelixis10 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Aclaris Therapeutics9 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
Addex Therapeutics9 shared keywordsAddex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Amylyx7 shared keywordsAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.

Companies competing with Artax Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Artax Biopharma do?
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.
Who founded Artax Biopharma?
Artax Biopharma was founded by Damia Tormo in 2013.
Who are Artax Biopharma's investors?
Artax Biopharma's investors include Sound Bioventures, Advent Life Sciences, Columbus Venture Partners.
How much funding has Artax Biopharma raised?
Artax Biopharma has disclosed $54.7M raised across 7 rounds.
Where is Artax Biopharma headquartered?
Artax Biopharma is headquartered in Cambridge, US.